Administration study of recombinant human relaxin-2 in horse for doping control purpose

• Published in: Drug testing and analysis Vol. 12; no. 3; p. 361
• Main Authors: Kwok, Wai Him, Choi, Timmy L S, Leung, Gary N W, Wong, April S Y, Yue, Samuel K, Wan, Terence S M, Ho, Emmie N M
• Format: Journal Article
• Language: English
• Published: England 01.03.2020
• Subjects: nano-ultra performance liquid chromatography/high resolution mass spectrometry; horse plasma and urine; doping control; human relaxin; administration study
• ISSN: 1942-7611
• DOI: 10.1002/dta.2732

The insulin-like peptide relaxin (RLX), an endogenous peptide hormone produced in human for pregnancy and reproduction, is also known to exert a range of physiological and pathological effects. Its use is banned in human sports, horseracing, and equestrian competitions due to its potential performance enhancing effect through vasodilation resulting in the increase of blood and oxygen supplies to muscles. Little is known about the biotransformation and elimination of RLX in horses. This paper describes an administration study of rhRLX-2 and its elimination in horses, and the development of sensitive methods for the detection and confirmation of rhRLX-2 in both horse plasma and urine by nano-liquid chromatography/high resolution mass spectrometry (nano-LC/HRMS) after immunoaffinity extraction with the objective of controlling the abuse of rhRLX-2 in horses. The limits of detection in plasma and urine are 2 pg/mL and 5 pg/mL, respectively. Two thoroughbred geldings were each administered one dose of 10 mg rhRLX-2 subcutaneously daily for 3 consecutive days. The rhRLX-2 could be detected and confirmed in the plasma and urine samples collected 105 h and 80 h, respectively, after the last dose of administration. For doping control purposes, rhRLX-2 ELISA could be used as a screening test to identify potential positive samples for further investigation using the nano-LC/HRMS methods.